
Life sciences investment continues to climb across the EU

Corporate, PE & late-stage life sciences VC deal activity



Source: PitchBook | Geography: Europe (excluding the UK) *As of June 22, 2021



\$3.5B

Sum generated by investment into EU-based life sciences companies through June 22 across 159 completed deals



51.1%

Share of deals closed for \$25 million or less across the EU's life sciences ecosystem in 2020, comprising 191 transactions that generated \$1.3 billion in total



\$1E

Tally of investment into drug discovery platforms across 27 transactions closed YTD, giving the subsegment the highest tally of deal value in 2021 thus far



71%

Share of overall funding for life sciences coming from late-stage VC investment at \$2.5 billion across 6 financings YTD, a strong pace relative to the \$4.0 billion recorded in 2020



\$3.3B

Exit value generated YTD by public listings of life sciences companies in the EU following a record-setting year in 2020, with \$5.4 billion in value generated by debuts on the public markets last year



58


The number of investments made by sovereign wealth fund Bpifrance, the most prolific investor of any type into EUbased life sciences companies since the start of 2006






"Although a far smaller market than that of the US, life sciences companies in the EU have benefitted in recent years from the rapid rise of dealmaking in the private markets, which pushed the CAGR for value to 9% since 2010 on a 8% annual increase in volume."


ANTHONY SHARRATT. HEAD OF VENUE EMEA & MENA








Source: PitchBook | Geography: Europe *As of June 22, 2021



Source: PitchBook | Geography: Europe *As of June 22, 2021



Source: PitchBook | Geography: Europe *As of June 22, 2021